He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking ...
While 2015 was marked by great announcements in the field of immunotherapy – particularly in melanoma and non-small cell lung cancer (NSCLC), this year’s American Society of Clinical Oncology ...
The results of the trial will be presented at the ASCO cancer congress tomorrow, and simultaneously published in The Lancet Oncology journal. The SYMPLIFY trial is one of two large-scale community ...
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its ...
The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors ...
Hosted on MSN10d
FDA approved drug achieves 100% remission for rectal cancerThe battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...
Nataliya Mar, MD, is associate clinical professor in the Division of Hematology/Oncology at the School of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback